[Cytostatic treatment of genital carcinoma].
D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000401:mortality; D005860:Germany, West; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011035:Podophyllum / Q000627:therapeutic use; D013852:Thiotepa / Q000627:therapeutic use; D014228:Triaziquone / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000627:therapeutic use
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D014747:Vinblastine; D003520:Cyclophosphamide; D013852:Thiotepa; D014228:Triaziquone; D008727:Methotrexate
Die zytostatische Behandlung der Genitalkarzinome.